Abstract
AMAÇ: Bu çalışmanın amacı, tümör nekrosis faktör-alfa (TNF-α) bloke edici ajanları kullanan ankilozan spondilitli (AS) hastaları tanımlamak ve klinik pratikte bu tedavinin etkinliği ve güvenliği ile ilgili verileri sunmaktı. YÖNTEMLER: Bu retrospektif çalışmaya, en az altı aydır TNF-α blokörleri kullanan AS’li hastalar dahil edildi. Anti-TNF-α ilaçların etkinliği ve güvenliğini düzenli klinik gözlemler ile değerlendirdik. Yan etkiler kaydedildi. Tedavi bırakma sebebleri de yakından takip edildi. Tüm hastalar ayrıntılı romatolojik değerlendirmeden geçirildi ve üç ayda bir AS özgü hastalık indeksleri yanı sıra laboratuar testleri ile rutin klinik pratikte izlendi. BULGULAR: Ortalama yaşları 43.22 yıl olan 26 erkek ve 15 bayan olmak üzere toplam 41 AS’li hasta gözden geçirildi. Etanersept ile tedavi edilen hasta sayısı 18 (%43,9), adalimumab ile 15 (%36,6), golimumab ile 3 (%7,3) ve son olarak infliximab ile 5 (%12,2) idi. AS’li hastalar için ortalama TNF-α blokör kullanım süreleri 39,56 ay idi. İlk anti-TNF-α tedavisi başarısız olan onbir (%26,8) hastanın yedisinde başka bir anti-TNF-α ajana geçildi. Diğer taraftan dört AS’li hasta anti-TNF-α tedaviyi bıraktı. AS özgü hastalık indeks ve laboratuar testleri üçüncü ve altıncı ayda TNF-α blokör başlangıcına göre düzelme gösterdi.SONUÇ: Klinik ortamımızda AS’li hastaların takibi anti-TNF tedavisinin iyi uyum oranları ile etkin ve güvenli bir tedavi yöntemi olduğunu göstermiştir.
Abstract
OBJECTIVE: The aim of this study was to describe ankylosing spondylitis (AS) patients using tumor necrosis factor-alpha (TNF-α) blocking agents and present the data on the efficacy and safety of this treatment in clinical practice. METHODS: AS patients using TNF-α blockers for at least six months were included in this retrospective study. We analysed efficacy and safety of the anti-TNF-α drugs with regular clinical observation. Adverse events were recorded. Reasons for treatment discontinuation were also closely followed-up. All patients received a comprehensive rheumatologic assessment at baseline and were monitored repeatedly in every three months in routine clinic practice with AS spesific disease indexes as well as laboratory tests. RESULTS: A total of 41 patients with AS were reviewed of whom 26 were male and 15 were female, with a mean age of 43.22 years. The number of AS patients who were treated with etanercept was 18 (43.9%), adalimumab was 15 (36.6%), golimumab was 3 (7.3%) and finally infliximab was 5 (12.2%). Mean duration of the TNF-α bloker usage for AS patients was 39.56 months. Seven of 11 (26.8%) AS patients who failed first anti-TNF-α therapy were switched to another anti-TNF-α agent. On the other hand four AS patients gave up anti-TNF-α therapy. AS spesific disease index scores and laboratory tests were improved at the third and the sixth months when compared with the scores at the initiation of the TNF-α bloker therapy.CONCLUSION: Follow-up of patients with AS in our clinical setting showed that anti-TNF therapy is an effective and safe way of treatment with good adherence rates.
Details
| Other ID | JA85GD47CU |
|---|---|
| Journal Section | Research Article |
| Authors | |
| Publication Date | October 1, 2014 |
| Submission Date | October 1, 2014 |
| Published in Issue | Year 2014 Issue: 3 |
